Trends Immunol. 2025 Dec 17:S1471-4906(25)00311-4. doi: 10.1016/j.it.2025.12.003. Online ahead of print.

ABSTRACT

Estrogen receptor (ER)⁺ breast malignancies are poorly infiltrated by immune cells, hence exhibiting limited sensitivity to immune checkpoint inhibitors (ICIs). Recent data from Palomeque et al. demonstrate that ER signaling actively contributes to such an immunoevasive phenotype by preventing the nuclear factor LCOR from establishing an ICI-sensitive tumor microenvironment.

PMID:41412836 | DOI:10.1016/j.it.2025.12.003